Neogenomics Inc

NEO exhibits a classic Blow-Off Top at recent highs, signaling exhaustion after a parabolic rally. While the long-term trend remains intact above the rising 200-day SMA, medium-term directional asymmetry has turned bearish due to the unsustained spike and heavy volume exhaustion. In the short term, price is pulling back into the 9-day EMA without a clear breakdown, indicating that selling should be deferred until rallies into structural resistance near the prior spike high.

• ↑Q2 revenue of $201.7M rose 11% YoY, beating guidance
• ↑NGS revenue surged 26% YoY, now ~33% of clinical revenue
• ↓Non-clinical pharma revenue fell 26% YoY, pressuring mix